Silva J, Azevedo T, Ferreira R, Neuparth M, Seixas F, Ginja M
Life (Basel). 2025; 15(2).
PMID: 40003658
PMC: 11856199.
DOI: 10.3390/life15020250.
Abukhalil M, Al-Alami Z, Alfwuaires M, Imran M, Aladaileh S, Althunibat O
Cardiovasc Toxicol. 2025; 25(3):455-470.
PMID: 39827225
DOI: 10.1007/s12012-025-09962-w.
Qin J, Yang Q, Wang Y, Shi M, Zhao X, Zhou Y
Front Pharmacol. 2024; 15:1377359.
PMID: 38868667
PMC: 11168204.
DOI: 10.3389/fphar.2024.1377359.
Angrisano T, Varrone F, Ragozzino E, Fico A, Minchiotti G, Brancaccio M
Int J Mol Sci. 2023; 24(15).
PMID: 37569627
PMC: 10419258.
DOI: 10.3390/ijms241512251.
Zhazykbayeva S, Hassoun R, Herwig M, Budde H, Kovacs A, Mannherz H
Front Cardiovasc Med. 2023; 10:1157398.
PMID: 37363100
PMC: 10285478.
DOI: 10.3389/fcvm.2023.1157398.
Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
De Lorenzi A, Kaplinsky E, Zambrano M, Chaume L, Rosas J
Drugs Context. 2023; 12.
PMID: 36660013
PMC: 9828870.
DOI: 10.7573/dic.2022-7-1.
Vascular dysfunction in HFpEF: Potential role in the development, maintenance, and progression of the disease.
Saavedra-Alvarez A, Pereyra K, Toledo C, Iturriaga R, Del Rio R
Front Cardiovasc Med. 2023; 9:1070935.
PMID: 36620616
PMC: 9810809.
DOI: 10.3389/fcvm.2022.1070935.
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y, Gao T, Meng C, Li S, Bi L, Geng Y
Eur J Med Res. 2022; 27(1):314.
PMID: 36581880
PMC: 9798580.
DOI: 10.1186/s40001-022-00945-z.
Apitherapy combination improvement of blood pressure, cardiovascular protection, and antioxidant and anti-inflammatory responses in dexamethasone model hypertensive rats.
Abd El-Hakam F, Abo Laban G, Badr El-Din S, Abd El-Hamid H, Farouk M
Sci Rep. 2022; 12(1):20765.
PMID: 36456799
PMC: 9714403.
DOI: 10.1038/s41598-022-24727-z.
Cardioprotective Effect of Taxifolin against Isoproterenol-Induced Cardiac Injury through Decreasing Oxidative Stress, Inflammation, and Cell Death, and Activating Nrf2/HO-1 in Mice.
Obeidat H, Althunibat O, Alfwuaires M, Aladaileh S, Algefare A, Almuqati A
Biomolecules. 2022; 12(11).
PMID: 36358896
PMC: 9687704.
DOI: 10.3390/biom12111546.
Altered Cellular Protein Quality Control System Modulates Cardiomyocyte Function in Volume Overload-Induced Hypertrophy.
Gomori K, Herwig M, Hassoun R, Budde H, Mostafi N, Delalat S
Antioxidants (Basel). 2022; 11(11).
PMID: 36358581
PMC: 9686542.
DOI: 10.3390/antiox11112210.
Cardiac fibrosis in oncologic therapies.
Packard R
Curr Opin Physiol. 2022; 29.
PMID: 36187050
PMC: 9518957.
DOI: 10.1016/j.cophys.2022.100575.
Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction.
Budde H, Hassoun R, Mugge A, Kovacs A, Hamdani N
Front Physiol. 2022; 13:928232.
PMID: 35874547
PMC: 9301384.
DOI: 10.3389/fphys.2022.928232.
Clinical Evidence and Proposed Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?.
Deschaine B, Verma S, Rayatzadeh H
Card Fail Rev. 2022; 8:e23.
PMID: 35846984
PMC: 9272408.
DOI: 10.15420/cfr.2022.11.
The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: Molecular mechanisms, roles and therapeutic potential.
Zhang X, Zhang Y, Sun A, Ge J
Genes Dis. 2022; 9(4):959-972.
PMID: 35685463
PMC: 9170600.
DOI: 10.1016/j.gendis.2021.04.001.
SARS-CoV-2 infects human cardiomyocytes promoted by inflammation and oxidative stress.
Tangos M, Budde H, Kolijn D, Sieme M, Zhazykbayeva S, Lodi M
Int J Cardiol. 2022; 362:196-205.
PMID: 35643215
PMC: 9132721.
DOI: 10.1016/j.ijcard.2022.05.055.
Wearable Devices for Physical Monitoring of Heart: A Review.
Prieto-Avalos G, Cruz-Ramos N, Alor-Hernandez G, Sanchez-Cervantes J, Rodriguez-Mazahua L, Guarneros-Nolasco L
Biosensors (Basel). 2022; 12(5).
PMID: 35624593
PMC: 9138373.
DOI: 10.3390/bios12050292.
Ca2+/calmodulin-dependent protein kinase II and protein kinase G oxidation contributes to impaired sarcomeric proteins in hypertrophy model.
Gomori K, Herwig M, Budde H, Hassoun R, Mostafi N, Zhazykbayeva S
ESC Heart Fail. 2022; 9(4):2585-2600.
PMID: 35584900
PMC: 9288768.
DOI: 10.1002/ehf2.13973.
Systemic Action of Inflammatory Mediators in Patients with Essential Hypertension and Diastolic Chronic Heart Failure: A Clinical Pathophysiological Study.
Barsukov A, Seidova A, Shcherbakova K, Black M, Korovin A, Churilov L
Pathophysiology. 2022; 27(1):30-43.
PMID: 35366254
PMC: 8830453.
DOI: 10.3390/pathophysiology27010005.
Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies.
Mongirdiene A, Skrodenis L, Varoneckaite L, Mierkyte G, Gerulis J
Biomedicines. 2022; 10(3).
PMID: 35327404
PMC: 8945343.
DOI: 10.3390/biomedicines10030602.